Politics
The Next Few Months Will Determine If The Future Of Hemp THC Products Is Regulation Or Prohibition (Op-Ed)
“The coming weeks will show whether the one-month reprieve becomes a bridge to lasting regulatory clarity or simply a brief postponement of an existential deadline.”
By Matt Ginder, Greenspoon Marder
For years, the hemp industry has occupied a unique and controversial space within the broader cannabis economy. What began as a niche agricultural market under the 2018 Farm Bill has grown into a multibillion-dollar industry spanning CBD products, THC beverages, edibles and more.
Today, the hemp industry faces its greatest challenge yet: a federal restriction that many stakeholders warn will fundamentally reshape—or even eliminate—a large share of the market, raising urgent questions for thousands of businesses.
The threat is no longer theoretical. A federal law enacted in 2025 imposed new restrictions on hemp-derived cannabinoid products, originally set to take effect in November 2026. That deadline has now shifted, but only briefly, and only for part of the market.
For readers who haven’t followed the issue closely, understanding how the industry reached this point is essential.
How Hemp Became A Cannabis Success Story
The modern hemp industry emerged after Congress passed the 2018 Farm Bill, which removed hemp and the THC it contains from the federal definition of marijuana. Hemp was defined by its delta-9 THC concentration: no more than 0.3 percent by dry weight. That distinction opened the door for farmers to cultivate hemp legally at scale.
The 2018 Farm Bill addressed cultivation, not finished products. It expressly preserved the Food and Drug Administration’s (FDA) existing authority over food, drugs and cosmetics. Yet FDA largely took a hands-off approach to hemp products intended for consumption.
That combination—a new legal definition of hemp, silence on finished products and minimal FDA enforcement—created the conditions for a wide variety of consumable hemp products to emerge. What followed was explosive growth. Some companies developed brands using hemp cannabinoids (compounds of the plant) aimed at wellness consumers, while others focused on intoxicating cannabinoids such as hemp-derived THC products.
Because finished hemp products were not treated as federally controlled substances, companies operating in this space enjoyed certain freedoms not offered to the marijuana industry—nationwide manufacturing, distribution and sale, unconstrained by state borders.
For instance, a consumer in Florida can order an intoxicating hemp product online from a company located in Minnesota, pay with a credit card, and have it delivered to their door by a major carrier. Interstate commerce, usage of credit cards, and the shipment of products remain prohibited in the marijuana industry.
Brick-and-mortar access has expanded just as quickly. While marijuana products are typically sold only through licensed dispensaries, hemp products can be purchased through traditional retail outlets, including convenience stores, liquor stores and grocery chains.
As the market advanced, so did scrutiny. Regulators and lawmakers raised concerns about product safety, potency, youth access, labeling and inconsistent state regulations. Those concerns became the driving force behind the push for stricter federal oversight.
The New Restrictions And Why They Matter
The 2025 federal restrictions narrow the legal definition of hemp considerably. Many products currently sold nationwide would no longer qualify as hemp. This threshold change will eliminate large segments of the cannabinoid marketplace.
For businesses that have invested heavily in manufacturing, supply chains and retail distribution, the stakes are high. At least one study estimates the sector generates well over $28 billion in the U.S. annually. If the restrictions take effect without modification, the sector will face severe disruption and contraction.
The ripple effects would extend well beyond manufacturers. Farmers who grow hemp for cannabinoid extraction could see demand sharply decline. Retailers that depend on hemp-derived product sales could lose a significant revenue stream. And consumers who now rely on legal hemp products could see many of those options disappear.
Divided Lines
Critics of the current framework view it as a de facto legalization of intoxicating cannabis through an unintended loophole in the 2018 Farm Bill. They argue that today’s products are inadequately regulated and too easily accessible, particularly to minors, and that stronger safeguards are necessary, especially for hemp products that have intoxicating effects.
Many marijuana industry stakeholders, meanwhile, see the hemp sector as a competitor that has operated free of the regulatory burdens the marijuana industry has long carried, and are pushing hard to reform.
The politics cut across party lines. The clearest illustration may be Kentucky’s two Republican senators: Mitch McConnell, who championed the 2018 Farm Bill, was one of the leading voices pushing to close the “hemp loophole” he helped create, while Rand Paul has emerged as one of the restrictions’ fiercest opponents.
The White House has also weighed in, openly opposing the restriction in a letter addressed to the speaker of the House.
Even the alcohol industry is split, with certain beer and spirits manufacturers largely supporting restrictions on hemp-derived THC beverages, while distributors, wholesalers, and retailers push to keep those products on the shelf.
Why The Hemp Industry Has Reason For Cautious Optimism
Despite the looming deadline, recent developments in Washington, D.C. have given the hemp industry a reason for cautious optimism.
Last month the Senate passed a continuing resolution, by a vote of 90–6, that would delay the effective date of most of the new hemp restrictions from November 12 to December 11. A Republican-led effort to strip the delay from the bill, spearheaded by Senator Ted Budd (R-NC), failed 61–32. Multiple outlets reported that President Donald Trump personally called Budd in the days before the vote to make the administration’s case for the delay, though a Budd spokesperson said the president did not directly ask him to withdraw his amendment.
This week, the House passed the Senate’s continuing resolution, including the one-month delay language. Trump signed the measure into law the next day, giving industry stakeholders a brief but meaningful window to continue advocating for longer-term regulatory solutions.
The delay is narrower than it may first appear: it applies to hemp-derived cannabinoids that occur naturally in the cannabis plant. Products containing synthetic cannabinoids (i.e., those not capable of being naturally produced by the plant) would still be reclassified as marijuana under federal law on the original November 12 date.
Beyond the short-term delay, several longer-term legislative fixes are circulating in Congress.
The Lawful Hemp Protection Act, from Reps. Andy Barr (R-KY) and Angie Craig (D-MN), would establish a federally taxed and regulated framework for hemp-derived products, while the Hemp Safety Enforcement Act, from Paul and Sen. Amy Klobuchar (D-MN), would shift primary regulatory authority to states and tribal governments. A third, bipartisan bill titled the Beverage Regulatory Parity Act, from Reps. Beth Van Duyne (R-TX) and Greg Landsman (D-OH) focuses narrowly on regulating hemp-derived beverages under a system comparable to alcohol.
None of these proposals have yet to gain the traction needed to move independently, but industry groups view the one-month reprieve as a critical window to build support for a regulatory solution.
What Industry Stakeholders Are Doing Now
With the outcome still uncertain, hemp businesses are increasingly focused on advocacy.
Trade groups, farmers, processors, manufacturers, retailers and consumers are urging lawmakers to pursue regulation over prohibition, with messaging centered on three themes: preserving jobs, protecting the hemp farming industry and establishing standards for cannabinoid products.
In practical terms, companies should be using this window to stress-test contingency plans, diversify product lines and prepare for compliance changes should the restrictions ultimately take effect, whether on December 11 or a later date.
The Road Ahead
The next few months could determine the future of the hemp-derived cannabinoid market in the U.S.
The president’s signing of the ban delay measure into law gives the industry a critical one-month window before the new December 11 deadline. What happens during that window will matter as much as the delay itself. Industry stakeholders, lawmakers and advocacy groups will have a brief but meaningful opportunity to pursue a legislative fix.
Absent consensus, Congress could instead pursue another short-term delay, buying additional time without resolving the underlying policy questions. And if neither a permanent fix nor a further delay materializes before December 11, the industry would face the restrictions as originally enacted, with natural hemp-derived cannabinoids joining synthetics under the marijuana classification.
As Congress weighs consumer safety, agricultural investment and market stability against each other, the hemp industry remains in an unusually precarious position, fighting not just for favorable policy, but for the survival of significant parts of its current business model.
The coming weeks will show whether the one-month reprieve becomes a bridge to lasting regulatory clarity or simply a brief postponement of an existential deadline.
Matthew Ginder is a partner in the Cannabis Law practice group at Greenspoon Marder LLP and represents various cannabis and hemp-related businesses where he assists in many areas of the industry, including licensing, regulatory and compliance and business transactions. He also represents ancillary businesses that provide products or services to the cannabis industry and advises individuals, investors, lenders, startups and large corporations on direct and indirect participation in state-legal cannabis markets.
Photo courtesy of Brian Shamblen.
